Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07364786
PHASE2

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

Sponsor: Peter Siesjö

View on ClinicalTrials.gov

Summary

The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.

Official title: Intratumoral Pressure, Intratumoral Partial Oxygen Pressure, and Inflammatory Cytokines in Antisecretory Factor Treatment of Glioblastoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2024-10-07

Completion Date

2026-11

Last Updated

2026-01-23

Healthy Volunteers

No

Conditions

Interventions

DIETARY_SUPPLEMENT

Salovum

Ingestion of Salovum 11g three times daily during 48 hours

Locations (1)

Department of Neurosurgery, Skane University Hospital

Lund, Sweden